Literature DB >> 27448183

Multiple sclerosis: Dimethyl fumarate is coming of age.

Mar Tintoré1, Jaume Sastre-Garriga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27448183     DOI： 10.1038/nrneurol.2016.106

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

1.  European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

Authors:  A Nast; P Gisondi; A D Ormerod; P Saiag; C Smith; P I Spuls; P Arenberger; H Bachelez; J Barker; E Dauden; E M de Jong; E Feist; A Jacobs; R Jobling; L Kemény; M Maccarone; U Mrowietz; K A Papp; C Paul; K Reich; S Rosumeck; T Talme; H B Thio; P van de Kerkhof; R N Werner; N Yawalkar
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-10-19       Impact factor: 6.166

2.  PML in a patient with lymphocytopenia treated with dimethyl fumarate.

Authors:  Thorsten Rosenkranz; Mark Novas; Christoph Terborg
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

3.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

4.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

5.  The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.

Authors:  Bhupendra O Khatri; Jeffery Garland; Joseph Berger; John Kramer; Lisa Sershon; Tayo Olapo; Jean Sesing; Mary Dukic; Eileen Rehn
Journal:  Mult Scler Relat Disord       Date:  2015-05-14       Impact factor: 4.339

Review 6.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

7.  Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.

Authors:  Melanie S Brennan; Maria F Matos; Bing Li; Xiaoping Hronowski; Benbo Gao; Peter Juhasz; Kenneth J Rhodes; Robert H Scannevin
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

8.  Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Authors:  Ralf Gold; Douglas L Arnold; Amit Bar-Or; Michael Hutchinson; Ludwig Kappos; Eva Havrdova; David G MacManus; Tarek A Yousry; Carlo Pozzilli; Krysztof Selmaj; Marianne T Sweetser; Ray Zhang; Minhua Yang; James Potts; Mark Novas; David H Miller; Nuwan C Kurukulasuriya; Robert J Fox; Theodore J Phillips
Journal:  Mult Scler       Date:  2016-07-11       Impact factor: 6.312
  8 in total
  1 in total

1.  Protection of Male Rat Offspring against Hypertension Programmed by Prenatal Dexamethasone Administration and Postnatal High-Fat Diet with the Nrf2 Activator Dimethyl Fumarate during Pregnancy.

Authors:  Chien-Ning Hsu; Yu-Ju Lin; Hong-Ren Yu; I-Chun Lin; Jiunn-Ming Sheen; Li-Tung Huang; You-Lin Tain
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.